Abstract 5862: NCI Office of Cancer Genomics supports multidisciplinary genomics research initiatives to advance precision oncology
Authors: Kyi Cindy W. , Birriel Pamela C. , Davidsen Tanja M. , Ferguson Martin L. , Gesuwan Patee , Griner Nicholas B. , He Yiwen , Hurd Lauren M. , Jagu Subhashini , Tonsing-Carter Eva , Gerhard Daniela S. 
Published: September 2020

Abstract
The National Cancer Institute's (NCI) Office of Cancer Genomics' (OCG) mission is to advance the molecular understanding of cancers to improve clinical outcomes. To accomplish this goal, OCG develops and collaboratively manages molecular characterization and translational genomics research initiatives. OCG currently supports four innovative and complementary initiatives. These programs generate comprehensive genomic datasets, develop bioinformatics tools to analyze these datasets, create biologically-relevant human tumor-derived Next-Generation Cancer Models (NGCMs) and valuable experimental reagents and resources.
The Cancer Genome Characterization Initiative (CGCI) (https://ocg.cancer.gov/programs/cgci) and the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) (https://ocg.cancer.gov/programs/target) are the molecular characterization programs. These programs aim to identify therapeutic targets and biomarkers in understudied, rare, and high-risk adult and pediatric cancers. Clinically annotated tumor and normal matched tissue samples are collected and analyzed by whole-genome, whole-exome, and transcriptome sequencing. The datasets are available to the research community through program-specific Data Matrices: CGCI Data Matrix and TARGET Data Matrix. CGCI and TARGET data are also available through NCI's Genomic Data Commons (GDC)(https://portal.gdc.cancer.gov/). The Pediatric Genomic Data Inventory (PGDI) is a global inventory of pediatric molecular and clinical datasets.
The CTD2 Network (https://ocg.cancer.gov/programs/ctd2) aims to understand cancer metastasis, tumor heterogeneity and drug resistance, and develop optimal combinations of pharmacologic and immunological agents. The CTD2 Network develops bioinformatics tools, generates diverse raw/primary datasets that can be accessed through the CTD2 Data Portal and further validates subsets of these data listed at the CTD2 Dashboard. The Human Cancer Models Initiative (HCMI) (https://ocg.cancer.gov/programs/HCMI) is an international consortium that is generating human tumor-derived NGCMs from diverse tumor subtypes including rare and pediatric cancers. The models, together with related clinical and genomic data, are available as a community resource. The HCMI Searchable Catalog allows users to search the list of available models and associated clinical and molecular data. The clinical and molecular data are stored at the NCI's GDC.
Data, analytical tools, and resources generated by OCG initiatives are made publicly available to further the collaborative goal of enabling precision oncology to improve patient care. The OCG website (https://ocg.cancer.gov/) also provides data usage policies, guides to access data, experimental methods, standard operating procedures, and educational and helpful links for the community.
Citation Format: Cindy W. Kyi, Pamela C. Birriel, Tanja M. Davidsen, Martin L. Ferguson, Patee Gesuwan, Nicholas B. Griner, Yiwen He, Lauren M. Hurd, Subhashini Jagu, Eva Tonsing-Carter, Daniela S. Gerhard. NCI Office of Cancer Genomics supports multidisciplinary genomics research initiatives to advance precision oncology [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5862.